Posted on

cbd for systemic scleroderma

Cbd for systemic scleroderma

What are the treatments for scleroderma?

What is scleroderma and how is it treated

However, CBD, which is one of the most widely used cannabinoids in alternative medicine, can relieve the inflammation that is the most troublesome symptom of scleroderma. Inflammation is reduced, but does not disappear completely. In addition, CBD can relieve pain in the case of joint damage.

In what form should CBD be used to relieve the symptoms of scleroderma?

In order to relieve widespread pain and inflammation, CBD oil can be ingested. The best way to have a quick absorption is to put a few drops under your tongue (sublingual route) and roll them around until fully absorbed.

Cbd for systemic scleroderma

Furthermore, CBD oil for scleroderma symptoms has an excellent safety profile. CBD itself causes very few side effects.

Although research into CBD for scleroderma is currently lacking, several trials are exploring the action of synthetic cannabinoids. Until these medications become more widely available, CBD oil could be well worth a try.

Cannabidiol (CBD) is a popular choice for patients suffering from a range of different ailments. Its proponents claim that it can help with everything from epilepsy to anxiety and insomnia to chronic pain. However, there is a new and exciting area of interest in CBD therapy – scleroderma.

In severe cases, more drastic treatments for scleroderma may be necessary. These could include surgery or newer techniques such as laser therapy and photodynamic therapy.

How Could CBD Oil Help Scleroderma?

Because CBD has only recently become well-known, there is limited clinical research on its benefits. However, it does appear to have potential anti-inflammatory effects. This is fantastic news for anyone who has scleroderma or other painful conditions, as inflammation is a leading cause of pain.

In scleroderma, the immune system attacks the connective tissue throughout the body.

This type of scleroderma only affects the skin. There are two types of localized scleroderma. They are known as morphea scleroderma and linear scleroderma.

Is CBD Oil Good for Scleroderma?

The ECS is present in almost all of the body’s tissues. It is a network of cell receptors and chemicals called endocannabinoids. These are compounds that the body produces naturally. They bind to cannabinoid receptors to trigger a variety of beneficial effects. Furthermore, endocannabinoids have a similar molecular shape to plant cannabinoids like CBD and THC.

A physician will be able to ensure that CBD oil is an appropriate option. They should also be able to guide you in finding the correct CBD dosage for scleroderma.

No reported significant side effects with CBD oil.

Results: The local treatment with CBD produced a significant reduction of SSU-related pain. After 1 month of therapy, pain VAS decreased from 94.8 ± 8.72 SD to 54.7 ± 9.4 SD (P<0.0001), total hours of sleep increased from 2.56 ±1.28 SD to 5.67 ± 0.85 SD (P <0.000). Additional analgesic therapy was necessary in 12/25 (48%). After 2 months, further clinical improvement was observed: the pain VAS reduced to 40.9 ± 12.9 SD, the mean total hours of sleep per night was 6.10 ± 0.85 SD and the HAQ-DI decreased from 1.1 ± 0.67 SD (baseline) to 0.46 ± 0.46 SD at the last patients’ evaluation, when complete healing of SSU and pain relief were obtained and CBD was discontinued. 20/25 (80%) pt registered a better compliance to the local wound management.

Background: Skin ulcers (SU) represent one of the most frequent complications of Systemic Sclerosis (SSc), characterized by severe chronic pain and frequent complications. Pain related to SSc SU(SSU) remains yet an area of significant unmet need. Moreover, pain control is fundamental for the wound care procedures in SSc patients (pt), increasing treatment adherence and compliance to skin ulcers dressing changes. The pain relief provided by standard therapy (i.e. NSAIDs, tramadol) is often inadequate or dose limited by side effects. Opioids currently are the mainstay of SSU pain treatment but burdened by side effect profile and/or ineffective. Thus, novel analgesic strategies need to be investigated. Cannabidiol (CBD), one of many constituents of the Cannabis sativa, has received renewed interest in the treatment of numerous pathological conditions.

Methods: 25 SSc pt (F/M 22/3, mean age 52.3 ± 12.9-SD-years), referred to our Scleroderma Unit during 2018, were consecutively included. In all pt the disease was complicated by long-standing, painful SU resistant to opioids. Pain was classified as severe, according to WHO guidelines in all subjects. 25/25 pt carried out systemic (calcium-channel blockers, prostanoids and/or anti-ET receptors) and local (debridement and dressing) therapies. The CBD (10% oral administration oil) was used daily for the treatment of SSU-related pain. We performed both an oral (five drops bid) as local treatment (two drops in the site of SSU) during surgical debridement of SSU for a period of 5.9 ± 3.2 SD months. Patients have been provided with a diary to record the following symptoms daily: self-evaluation of pain at the same time in the evening, using a visual analog scale (VAS), use of other analgesics, eventual side effects. Health assessment Questionnaire-Disability index (HAQ-DI) was administrated baseline and at the end of treatment. Safety of CBD was evaluated by patient’s records of side effects, while vital signs and laboratory parameter variations were monitored at each weekly medication.

Objectives: Evaluate our experience to define the efficacy of CBD preparation in patients with SSU.

Conclusion: Our study suggests that the use of CBD as a local therapy is effective and safe in maintaining analgesia in patients with SSU; not secondarily it could be essential for an adequate healing of a local wound with consequent improvement of SSc patients’ quality of life and compliance on local SSU management. Further larger-scale studies will be needed to finally demonstrate CBD efficacy and to monitor long-term effects.